Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
|
UK |
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
US |
|
S
|
Shanghai Chinafortune Co Ltd
SSE:600621
|
CN |
|
H
|
Hiap Teck Venture Bhd
KLSE:HIAPTEK
|
MY |
|
S
|
SICHUAN HEXIE SHUANGMA Co Ltd
SZSE:000935
|
CN |
|
New World Department Store China Ltd
HKEX:825
|
HK |
|
People's Insurance Company Group of China Ltd
SSE:601319
|
CN |
|
P
|
Primetech SA
WSE:PTH
|
PL |
|
Symphony International Holdings Ltd
LSE:SIHL
|
VG |
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
HK |
Barinthus Biotherapeutics PLC
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
